Phytocannabinoids such as β-caryophyllene (BCP), have a favorable oral bioavailability, a non-psychoactive effect, and may have the potential to modulate the activity of SGLT2 and thus be a useful drug in patients with T2DM [43]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.